Gilead Acquisition Of Corus Adds Respiratory Disease Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
Gilead exercised an option to buy the maker of the investigational inhaled antibiotic Cayston for $365 mil.
You may also be interested in...
Gilead Hopes To Dodge New Trial With CF Antibiotic
FDA’s complete response finds the Cayston NDA not approvable as is.
Gilead Hopes To Dodge New Trial With CF Antibiotic
FDA’s complete response finds the Cayston NDA not approvable as is.
Gilead’s Cystic Fibrosis Drug Looks Good Long-Term, Firm Reports
Convenience and tolerability benefits could position aztreonam lysine as best-in-class.